Painless Flu Vaccines

Posted: October 2nd, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , , , | Comments Off on Painless Flu Vaccines

Five years ago this summer, AstraZeneca decided to pony up to purchase Maryland-based MedImmune for a cool $15.6 billion, a deal that left many wondering whether the bills matched the product.  Now, incoming CEO Pascal Soriot has his work cut out for him.

Come October, the French-native will jump over from Roche , where he served as chief operating officer since 2010. He’s inheriting a vaccines and biotech drugs division with 2,600 Maryland employees and 4,000 globally, The Washington Post reports.  The company will also shutter two California offices, leading to a loss of 200 jobs and a shift of 100 more to other sites.

MedImmune has had its ups and downs, with the vaccines business supplying some upbeat results; in 2009, the company was the first to market a swine flu vaccine.  And this year MedImmune rolled out the first intranasal flu vaccine that contains four strains of the disease.

English: Millington, Tenn. (Oct. 28, 2005) &nd...

(Photo credit: Wikipedia)

Fluenz nasal spray became the vaccine of choice in the U.K. for children ages 2 to 17 in a contract expected to exceed £100 million ($156.7 million).  The company’s FluMist brought in $161 million of AZ’s $33.6 billion in revenue in 2011.

Comments are closed.